Open Access
| Issue |
BIO Web Conf.
Volume 182, 2025
The 3rd International Conference on Food Science and Bio-medicine (ICFSB 2025)
|
|
|---|---|---|
| Article Number | 02007 | |
| Number of page(s) | 5 | |
| Section | Biomedical Research and Applications | |
| DOI | https://doi.org/10.1051/bioconf/202518202007 | |
| Published online | 02 July 2025 | |
- Peng L, Sferruzza G, Yang L, et al. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors[J/OL]. Cellular & Molecular Immunology, 2024, 21(10): 1089–1108. DOI:10.1038/s41423-024-01207-0. [CrossRef] [PubMed] [Google Scholar]
- Simoni Y, Becht E, Fehlings M, et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates [J/OL]. Nature, 2018, 557(7706): 575–579. DOI:10.1038/s41586-018-0130-2. [CrossRef] [PubMed] [Google Scholar]
- Maleki Vareki S, GarrigÓS C, Duran I. Biomarkers of response to PD-1/PD-L1 inhibition[J/OL]. Critical Reviews in Oncology/Hematology, 2017, 116: 116–124. DOI:10.1016/j.critrevonc.2017.06.001. [CrossRef] [PubMed] [Google Scholar]
- Wallich R, Bulbuc N, HÄMmerling G, et al. Abrogation of metastatic properties of tumour cells by de novo expression of H–2K antigens following H–2 gene transfection[J]. Nature, 1985, 315(6017): 301–305. [CrossRef] [PubMed] [Google Scholar]
- Liu Z, Wang T, She Y, et al. N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer[J/OL]. Molecular Cancer, 2021, 20(1): 105. DOI:10.1186/s12943-021-01398-4. [CrossRef] [PubMed] [Google Scholar]
- Wen T, Barham W, Li Y, et al. NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy [J/OL]. Cancer Immunology Research, 2022, 10(2): 162–181. DOI:10.1158/2326-6066.CIR-21-0539. [CrossRef] [PubMed] [Google Scholar]
- Lizotte P H, Hong R L, Luster T A, et al. A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing[J/OL]. Cancer Immunology Research, 2018, 6(12): 1511–1523. DOI:10.1158/2326-6066.CIR-18-0193. [CrossRef] [PubMed] [Google Scholar]
- Zhong Y, Li M Y, Han L, et al. Galangin inhibits programmed cell death-ligand 1 expression by suppressing STAT3 and MYC and enhances T cell tumor-killing activity[J/OL]. Phytomedicine, 2023, 116: 154877. DOI:10.1016/j.phymed.2023.154877. [CrossRef] [PubMed] [Google Scholar]
- Xu H, van der Jeught K, Zhou Z, et al. Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation[J/OL]. Journal of Clinical Investigation, 2021, 131(10): e146832. DOI:10.1172/JCI146832. [CrossRef] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.